Short-Term Therapy with Rosiglitazone, a PPAR-𝜸 Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats

Figure 3

Relaxation curves for sodium nitroprusside (SNP) on arteries from 5-day rosiglitazone-treated and untreated control animals. NA (8 μM)-precontracted arteries were subjected to increasing concentration of SNP. There were no significant differences between the two groups. Data represent mean ± S.E.